Archive — US — techcrunch
Elon Musk’s Neuralink closes a $650M Series E
Elon Musk's Neuralink has secured $650 million in a Series E funding round led by prominent investors, raising its valuation to approximately $9 billion. The new funds will support ongoing human clinical trials for its brain chip technology, which recently received breakthrough designation from the FDA, following prior funding rounds totaling $323 million in 2023.
Key points
- Neuralink raised $650 million in Series E funding.
- Investors included ARK Invest, Founders Fund, Sequoia Capital, and Thrive Capital.
- Previous funding included $280 million in a Series D round and an additional $43 million.
- Neuralink has conducted human trials with brain chip implants in five individuals with severe paralysis.
- The FDA granted Neuralink breakthrough device designation to accelerate development and review.
- The company's valuation is reported around $9 billion pre-money.
Why it matters
- The funding raises awareness of the growing brain-computer interface sector.
- Similar ventures, like Synchron's efforts, highlight advancements in neurotechnology.
- The U.S. is increasingly supporting innovative medical technologies to address severe disabilities.
- Investments in health tech are on the rise as part of the digital transformation trend in 2025.
Neuralink's recent $650 million funding round marks a significant milestone in the advancement of brain-computer interface technology, showcasing its potential impact on medical treatments for paralysis and pushing the boundaries of neurotechnology innovation.